Health Equity Coalition for Chronic Disease

A nationwide coalition working to advance health equity and eliminate barriers to care and treatment for obesity and other chronic diseases.

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

The FDA just raised the alarm on compounded GLP-1 drugs. From unsanitary facilities to dosing errors leading to hospitalizations, there’s no replacement for FDA-approved care.

Millions of Americans turn to these risky alternatives every day because FDA-approved treatments aren't permanently covered by Medicaid or Medicare. It’s past time to change that. Join us in our fight to expand access to anti-obesity drugs.
https://t.co/aIOEeV2ZfI

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

We’re calling on you to help urge CA policymakers to restore Medi-Cal coverage for obesity medications, including GLP-1 therapies, that help reduce health disparities among vulnerable groups. Cutting access to proven treatments is a health equity issue.

➡️Sign the petition: https://t.co/DQ0ccnS2s9

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

The launch of Medicare’s GLP-1 Bridge Demonstration will allow beneficiaries to access GLP-1 weight-loss medications for just $50!

Our new fact sheet explains what patients should know and how they can access these treatments. https://t.co/u9IBuYAXoC

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

Consumers deserve safe, proven treatments—not misleading claims.

The FDA is proposing new limits on compounded GLP-1 drugs, citing safety and quality concerns. HECCD continues to call on the FTC to investigate deceptive telehealth marketing tied to these products.

🔗Read the full article to see what this means: https://t.co/OsK7mLsthh

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

A major win for health equity in Maryland.

SB 496 expands access to obesity treatment through Medicaid.

Now we’re calling on Gov. Wes Moore to sign it into law. Read more to see what’s at stake. 🖋️📜 https://t.co/PZVu6fB7hY

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

A major step forward for patient safety in Colorado. SB26-066 has passed the Senate and is helping protect communities from deceptive practices that promote misleading “copycat” GLP-1 drugs.

Now it’s on the House to take action.

Learn what’s at stake ⬇️ https://t.co/feOKku6FGu

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

Colorado lawmakers face a critical choice. Patients shouldn’t have to choose between access & safety.

Health equity leaders are urging passage of SB-26-066 to crack down on misleading “copycat” GLP-1 drugs targeting vulnerable communities

📖 Read more: https://t.co/fw7haPppXU

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

Nearly 1 in 3 adults in California lives with chronic obesity.

Now, cutting Medi-Cal coverage for anti-obesity medications has put patients like Shekinah at risk of losing life-changing care. Cutting coverage doesn’t reduce costs—it only shifts them while patients suffer.

📖 Read more: https://t.co/6y0UN7dWj6

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

Obesity in New Mexico has risen to 35%, with the highest rates among Hispanic and low-income communities.

A coalition of health organizations is urging the state to expand Medicaid coverage for weight-loss medications to reduce health disparities and prevent chronic disease.

Read More: https://t.co/xiUJX0wT1Y

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

https://t.co/5OQmYMvFkU

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

Obesity affects 42% of U.S. adults, yet many still lack access to recommended treatments. A new CMS initiative: the BALANCE Model could expand Medicare and Medicaid access to GLP-1 medications for eligible patients.

HECCD applauds this step. Click the links in our thread to learn more ⬇️:https://t.co/HmZefwUr4i

[Obesity Care Advocacy Network @ObesityAdvocacy]

The BALANCE model will expand access to obesity medications for Medicaid beneficiaries, helping improve health outcomes through more affordable, evidence-based treatment.

State Medicaid agencies can apply by July 31, 2026 to participate in the model.

https://t.co/HiPrhFRBHv

[Obesity Care Advocacy Network @ObesityAdvocacy]

@CMSGov is advancing the BALANCE model to expand affordable access to GLP-1 medications and obesity care for Medicare beneficiaries. But there’s not much time left!

Medicare Part D plans have to apply to participate by April 20, 2026.

https://t.co/llMsm0cYhv

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

Obesity-related conditions cost New Mexico $2B each year. Expanding Medicaid coverage is a smart, equitable investment. Read more from our partners at @LULAC
https://t.co/CyNn6eBXpD

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

The answer to unfair and discriminatory coverage barriers to accessing FDA-approved anti-obesity treatments in both the private insurance market and public health programs, is not leaving patients vulnerable to substitutes that may be both dangerous and a waste of money.

Learn more by reading our statement about FDA’s important actions to curb false claims by compounders.
https://t.co/taqHQRYdqx

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

New Dietary Guidelines highlight the role of healthy food in preventing chronic disease but guidelines aren’t enough without access. SNAP falls short in 99 U.S. counties, and nationally meals cost 20% more than SNAP benefits. We urge lawmakers and the administration to prioritize access to the communities who need it most.
https://t.co/Q5vQLAKzhc

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

California's decision to end Medi-Cal coverage for obesity medications is a step backward for health equity.

Black and Latino communities are disproportionately impacted by obesity and deserve access to modern, science-based care—not more barriers. #HealthEquity #ObesityCareNow https://t.co/sK3wFDX1Ha

[Health Equity Coalition for Chronic Disease @HealthEquityAct]

Pennsylvania's decision to restrict Medicaid coverage for life-changing GLP-1 obesity medications is a setback for #HealthEquity.

Restricting access to proven chronic disease prevention tools for is short-sighted. We must prioritize patient well-being and access to essential chronic disease management.

Read the full story from @SpotlightPA: https://t.co/4kcmkwuHPy